It is made available under a CC-BY-NC-ND 4.0 International license .

1	Gene Therapy Restores the Transcriptional Program of Hematopoietic Stem
2	Cells in Fanconi Anemia
3	
4	RUNNING TITLE
5	scRNA seq following Gene Therapy in FA HSPCs
6	
7	AUTHORS
8	Miren Lasaga ^{1*} , Paula Río ^{2,3,4*} , Amaia Vilas-Zornoza ^{5,6,*} , Nuria Planell ¹ , Susana Navarro ^{2,3,4} ,
9	Diego Alignani ⁷ , Beatriz Fernández-Varas ^{3,8} , Josune Zubicaray ⁹ , Roser M. Pujol ^{3,10,11} , Eileen
10	Nicoletti ¹² , Jonathan D. Schwartz ¹² , Julián Sevilla ^{3,9} , Marina Ainciburi ^{5,6} , Asier Ullate-Agote ^{5,6} ,
11	Jordi Surrallés ^{3,10,11} , Rosario Perona ^{3,8,13} , Leandro Sastre ^{3,8} , Felipe Prosper ^{5,6,&} , David Gomez-
12	Cabrero ^{1,14,15,&} and Juan A. Bueren ^{2,3,4,&} .
13	AFFILIATIONS
14	¹ Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra
15	(UPNA), IdiSNA, Pamplona, Spain.
16	² Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas,
17	Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.
18	³ Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
19	⁴ Instituto de Investigaciones Sanitarias. Fundación Jiménez Díaz, Madrid, Spain.
20	⁵ Area de Hemato-Oncología, Centro de Investigación Médica Aplicada (CIMA), and Servicio de
21	Hematologia y Terapia Celular, Clínica Universidad de Navarra, IDISNA, Pamplona, Spain.
22	⁶ Centro de Investigación Biomédica en Red de Cáncer, CIBERONC.
23	⁷ Flow Cytometry Core, CIMA, Universidad de Navarra, Pamplona, Spain.
24	⁸ Instituto de Investigaciones Biomédicas Alberto Sols, CSIC/UAM.
25	⁹ Hemoterapia y Hematología Pediátrica, Fundación para la Investigación Biomédica, Hospital
26	Infantil Universitario Niño Jesús, Madrid, Spain.
27	¹⁰ Departmento de Genética y Microbiología, Universitat Autónoma de Barcelona, Barcelona,
28	Spain;
	1

It is made available under a CC-BY-NC-ND 4.0 International license .

¹¹Fundación Instituto de Investigación del Hospital de la Santa Creu y Sant Pau, Barcelona, 29 Spain; 30 ¹²Rocket Pharmaceuticals Inc. New York, NY, USA 31 ¹³ Instituto de Salud Carlos III, Madrid, Spain 32 ¹⁴Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah 33 34 University of Science and Technology KAUST, Thuwal, Saudi Arabia. ¹⁵Mucosal & Salivary Biology Division King's College London Dental Institute, London, United 35 Kingdom. 36 37 *Equal first author contribution. 38 [&]Corresponding authors with equal contribution. Juan A. Bueren. Email: juan.bueren@ciemat.es; 39 David Gomez-Cabrero. david.gomezcabrero@kaust.edu.sa; Email: Felipe Prosper 40 Email:fprosper@unav.es. 41 42 **ABSTRACT** 43

Fanconi anemia (FA) is an inherited disease associated with marked hematopoietic stem and 44 progenitor cell (HSPC) defects. Ongoing clinical trials have shown that lentiviral-mediated gene 45 therapy can ameliorate bone marrow failure (BMF) in non-conditioned FA patients thanks to the 46 proliferative advantage of corrected FA HSPCs. Here we investigated whether gene therapy can 47 revert affected molecular pathways in diseased HSPCs, a question not previously addressed in 48 any HSC gene therapy trial. Single-cell RNA sequencing was performed in chimeric populations 49 50 of corrected and uncorrected HSPCs coexisting in BM of gene therapy treated FA patients. Our study demonstrates that gene therapy reverts the transcriptional signature of FA HSPCs, which 51 then resembles the transcriptional program of healthy donor HSPCs. This includes a 52 downregulated expression of TGF- β and p21, typically upregulated in FA HSPCs, and 53 upregulation of DNA damage response and telomerase maintenance pathways. Our results show 54 for the first time the potential of gene therapy to rescue defects in the HSPC transcriptional 55 program from patients with inherited diseases, in this case in FA characterized by BMF and 56 cancer predisposition. 57

58

It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION 59

60

The potential of gene therapy (GT) to correct a variety of human inherited diseases, including 61 primary immunodeficiencies and hemoglobinopathies has been well demonstrated in previous 62 clinical studies (Ferrari, Thrasher et al., 2021). Additionally, we have recently shown that 63 lentiviral-mediated GT can also enable correction of more complex diseases, such as Fanconi 64 anemia (FA), in which marked phenotypic defects are already evident in the self-renewing 65 HSCs. As previously reported, the infusion of corrected CD34⁺ cells in non-conditioned FA 66 patients resulted in a marked HSPC proliferative advantage, which facilitates the progressive 67 increase in the number of bone marrow (BM) and peripheral blood (PB) gene-corrected cells 68 (Rio et al., 2019). 69

Despite significant advances in the field of GT, the full potential of this therapeutic modality will 70 71 depend on its capacity to reestablish the molecular circuits and the functional potential of diseased cells. This is even more relevant in syndromes such as FA, characterized by DNA repair 72 73 defects resulting in progressive accumulation of DNA damage, and additional molecular responses triggered by a defective FA/BRCA pathway. In patients treated in the FANCOLEN-I 74 clinical trial, the presence of a chimeric population of corrected and uncorrected FA HSPCs. 75 none of them exposed to any conditioning agent, let us comparatively investigate the differential 76 77 molecular pathways that characterize each of these populations coexisting in the BM of these patients (Fig.1). This approach allowed us to demonstrate that lentiviral-mediated GT not only 78 mediates a progressive engraftment of FA patients with gene corrected HSPCs, but also results in 79 the reprogramming of the transcriptional signature of FA HSPCs, which then resembles the 80 molecular circuits of healthy HSPCs, thus accounting for the phenotypic correction of FA 81 HSPCs. 82

83 RESULTS

84

Gene therapy modifies the HSPC transcriptional program in FA patients

Bone marrow (BM) CD34⁺ cells from four FA-A patients (FA-02002, FA-02004, FA-02006, and 85 FA-02008) who had respectively been treated with gene therapy 5, 4, 3, and 2 years previously, 86 were purified and analyzed by single-cell RNA sequencing (scRNAseq), as described in Fig 1. 87

It is made available under a CC-BY-NC-ND 4.0 International license .

qPCR analyses from these samples showed the presence of 0.77 vector copy numbers (VCN) per cell in the BM of patient 02002, and 0.45, 0.26, and 0.29 VCNs per cell in purified CD34⁺ cells in patients FA-02004, FA-02006, and FA-02008 respectively (see Materials and methods). Since the average VCN per corrected cell was of 1.0 copies(Rio, Navarro et al., 2019), the proportion of corrected cells in these patients is estimated to be 77%, 45%, 26%, and 29%, respectively, revealing the chimeric nature of the HSPC populations residing in their BM.

CD34⁺ cells from FA patients were classified according to transcriptional profiles previously 94 described(Velten, Haas et al., 2017, Zheng, Terry et al., 2017), which identified twelve different 95 HSPC clusters that corresponded to primitive HSCs and more committed lympho-hematopoietic 96 progenitor cells (See analyses from patient FA-02006 in Fig. 2A; and patients FA-02002, FA-97 98 02004 and FA-02008 in Fig. S1A, B, C, D). To investigate the impact that GT had in the transcriptional program of FA HSPCs, CD34⁺ cell subpopulations from GT-treated FA patients 99 were classified as FANCA⁺ and FANCA⁻, based on the expression of FANCA by scRNAseq (see 100 materials and methods). As shown in **Fig. 2B** and **2C**, the presence of $FANCA^+$ cells was 101 102 evident in all HSPC populations represented with at least 30 cells per cluster. No significant differences in the proportion of FANCA⁺ cells present in these subpopulations were observed 103 among the four patients (Table S1). Additionally, a wide range of FANCA expression was 104 observed in samples analyzed, although higher expression levels were observed in most HSPC 105 subpopulations from patient FA02002, compared with the other patients (Fig. 2D). 106

To investigate the impact that ectopic FANCA expression had in the transcriptional program of 107 HSPCs, we performed a differential expression analysis between FANCA⁺ and FANCA⁻ HSPCs 108 present in each GT-treated patient. As shown in Fig. 2E, the ectopic expression of FANCA 109 110 upregulated a high number of genes compared to the number of genes that were downregulated. As expected, genes with statistically differential expression corresponded to subpopulations with 111 a higher representation (i.e., monocytic CD34⁺ cells; genes with significantly up-regulated and 112 down-regulated expression (p-value< 0.001) are shown in dark red and dark blue bars, 113 114 respectively in Fig. 2E). Remarkably, most of the upregulated and downregulated genes in FANCA⁺ vs. FANCA⁻ cells showed the same expression pattern in each of the analyzed patients 115 (see fifth bar at the bottom of each patient's bars in **Fig. 2E**). To select the genes with a robust 116 differential expression between FANCA⁺ versus FANCA⁻ HSPCs, we considered those genes 117

It is made available under a CC-BY-NC-ND 4.0 International license .

that showed a significant differential expression (abs(logFC)>0.25 and adjusted p-value<0.05) in
at least one cell type and in at least three patients. In addition, changes in gene expression should
be in the same direction in all the four patients. Based on these criteria, a total number of 152
differentially expressed genes were identified (See Table S2).

Taken together, data obtained in these analyses indicate that the ectopic expression of *FANCA* induced long-term reproducible changes in the gene expression program of HSPCs from FA-A patients.

Gene therapy reprograms the transcriptional signature of FA HSPCs towards the transcriptional profile characteristic of healthy HSPCs

Next, we investigated whether changes in the transcriptional program of gene-corrected FA-A 127 HSPCs resembled profiles characteristic of healthy HSPCs. To this end, scRNAseq data from 128 GT-treated FA CD34⁺ cells was compared with that obtained from HD CD34⁺ cells. As shown in 129 130 **Fig. 3A** (see also **Expanded View Figure S2**) the ectopic expression of *FANCA* (FANCA⁺ cells) was detected in the different $CD34^+$ cell clusters. Additionally, Fig. 3B shows that FANCA 131 expression levels in the different HSPC subpopulations are highly heterogeneous, not only in the 132 case of GT-treated FA patients, but also in HDs. Despite this heterogeneity, in eight out of the 133 twelve HSPC subpopulations, physiological levels of FANCA mRNA were significantly higher 134 in HD HSPCs compared with the corresponding values observed in FANCA⁺ HSPCs from GT-135 treated FA patients. This observation is consistent with the average insertion of 1 proviral 136 FANCA copy per corrected cell after GT, in comparison with the 2 copies of WT FANCA per HD 137 cell, and also with the moderate activity of the phosphoglycerate kinase (PGK) promoter that 138 was selected for the therapeutic vector because of its favorable safety profile. 139

To investigate if GT reprogrammed the transcriptional signature of FA HSPCs towards the one
corresponding to HD HSPCs, additional gene expression analyses were conducted in HD and FA
HSPCs, focusing on the 152 genes that showed significant expression changes between FANCA⁺
and FANCA⁻ HSPCs in GT treated patients (See Figure 2E and Table S2). In these studies,
three different comparisons were performed in each of the twelve HSPC subpopulations:
FANCA⁺ vs. FANCA⁻ HSPCs from GT-treated FA patients (GT-FA HSPCs); HD HSPCs vs.
FANCA⁻ GT-FA HSPCs; and finally, HD HSPCs vs. FANCA⁺ GT-FA HSPCs (Fig. 3C). As

It is made available under a CC-BY-NC-ND 4.0 International license .

observed in analyses of **Fig. 2**, significant differences (dark red or blue spots in **Fig. 3C**) were most evident in HSPC subpopulations with a higher representation (i.e. monocyte $CD34^+$ cells; p-value<0.001).

Regarding the comparison of GT-FANCA⁺ vs. GT-FANCA⁻ HSPCs (Fig. 3C first column), 150 151 several differentially expressed genes with relevance in FA have been marked (see right side of the figure). Interestingly, genes involved in functions such as DNA repair or cell cycle were 152 upregulated in GT-FANCA⁺ vs GT-FANCA⁻ cells. In the second column of **Fig. 3C**, the gene 153 expression pattern of HSPCs from HDs was compared with that corresponding to uncorrected 154 HSPCs from GT-treated patients (HD vs GT-FANCA⁻). Strikingly, most of the transcriptional 155 changes observed between these populations resembled changes seen between corrected and 156 uncorrected FA HSPCs (first column in Fig. 3C) (see Table S3 for detailed analyses per cell 157 type using two complementary statistical analyses). Finally, in contrast to the above-mentioned 158 159 observations, the comparison of the transcriptional program of HD HSPCs vs FANCA⁺ HSPCs from GT-treated FA patients (third column in Fig 3C) showed limited changes, most of which 160 were not significant and not related to differences noted when HD or corrected FA HSPCs were 161 compared with uncorrected FA HSPCs. Overall, these studies demonstrate that lentiviral-162 163 mediated GT reverts the gene expression program of FA HSPCs, which then acquire an expression pattern that resembles the signature characteristic of healthy HSPCs. 164

165 Lentiviral-mediated gene therapy reverts molecular pathways characteristic of FA HSPCs

Having observed that the ectopic expression of FANCA in FA HSPCs reverts the transcriptional 166 signature of these cells to resemble a healthy HSPC signature, we next performed a gene-set 167 enrichment analysis to determine changes in relevant pathways associated with FA. These 168 include pathways related to DNA damage response and repair, cell cycle checkpoint, cell aging, 169 and telomerase maintenance (see materials and methods). As shown in Fig. 4 and Table S4, an 170 upregulated expression of several of these pathways was observed when FANCA⁺ and FANCA⁻ 171 HSPCs present in each of the GT-treated patients were compared (See first paired columns in 172 Fig. 4; GT-FANCA⁺ vs GT-FANCA⁻). Moreover, an almost identical upregulation of these 173 pathways was observed when HSPCs from HDs were compared with FANCA⁻ HSPCs from GT-174 treated patients (HD vs GT-FANCA; second paired columns in Fig. 4). 175

176

It is made available under a CC-BY-NC-ND 4.0 International license .

177 A deeper comparative expression analysis of genes involved in the cell cycle control was then performed between FANCA⁺ and FANCA⁻ HSPCs from GT-treated patients (GT-FANCA⁺ vs 178 GT-FANCA⁻; see external crowns in **Fig. 5A**). Similar comparisons were also made between HD 179 HSPCs and FANCA⁻ HSPCs from GT-treated patients (internal crowns in Fig. 5A). As shown, 180 the ectopic expression of FANCA was associated with the downregulation of TGF- β in every 181 182 patient, and also of p21 (CDKNA1) in two of the four GT-treated FA patients. On the other hand, a number of cyclins and mini-chromosome maintenance (MCM) genes were upregulated in 183 corrected vs uncorrected FA HSPCs (FANCA⁺ vs FANCA⁻ HSPCs). Notably, when similar 184 comparisons were performed between HD HSPCs and FANCA⁻ HSPCs from GT-treated FA 185 patients, almost identical gene expression changes were observed (Fig. 5A), indicating that the 186 behavior of cell cycle and DNA checkpoint pathways in corrected FA-A HSPCs resembled the 187 pathways characteristic of healthy HSPCs. 188

189 Since previous studies have shown that p21 participates in the transcriptional repression of different genes of the FA/BRCA pathway (Jaber, Toufektchan et al., 2016, Rego, Harney et al., 190 191 2012) changes in the expression of FA/BRCA genes were also comparatively investigated in FANCA⁺ and FANCA⁻ HSPCs from GT-treated patients. As shown in **Fig. 5B**, in addition to 192 FANCA, several other genes participating in the FA/BRCA pathway, including FANCB, FANCI, 193 FANCD2, FANCG, UB2T (FANCT), BRCA2, PALB2, BRCA1 and BRIP1 (FANCJ) were 194 upregulated in GT-FANCA⁺ vs. GT-FANCA⁻ HSPCs. Again, many of these genes were also 195 upregulated when HD HSPCs were compared with uncorrected GT-FANCA⁻ HSPCs. 196

This set of studies thus demonstrate that GT reverts physiologically relevant molecular pathways
that are severely affected in HSPCs from FA patients

199 Functional implications of the restored transcriptional program of corrected FA- HSPCs

In a final set of experiments, we investigated the functional implications associated with the restored transcriptional program of gene corrected FA HSPCs. First, we investigated if the restored DNA repair pathways had a direct implication in the correction of the hypersensitivity of FA-HSPCs to inter-strand crosslinking agents such as mitomycin C (MMC). While colony forming cells (CFCs) from the four patients were highly sensitive to MMC prior to the infusion of corrected HSPCs (no colonies were generated when cells were exposed to 10 nM MMC),

It is made available under a CC-BY-NC-ND 4.0 International license .

survival of these cells to MMC was markedly increased 2 to 5 years after GT (22.3% to 67.3% of
 CFCs survived in 10 nM MMC; Figure 6A). Consistent with these studies, the percentage of T
 cells with diepoxybutane (DEB)-induced aberrant chromosomes was also markedly decreased
 after GT of FA-A patients (Figure 6B). Overall, these studies confirm the functional implications
 associated with the restoration of the DNA repair pathways observed in the scRNAseq analyses
 shown in Fig. 4.

212 Finally, since scRNAseq studies also showed the restoration of telomere maintenance pathways, we studied changes in the telomere length of PB cells from the four FA patients included in this 213 study. In particular, we evaluated changes that took place from the 15th day post-infusion, when 214 the proportion of corrected cells was still undetectable, to the 2nd -5th year post-infusion. As a 215 negative control, changes in the telomere length of PB cells from three FA-A patients with no 216 significant engraftment of corrected cells (VCN<0.008; control FA group) were investigated at 217 comparable time points. While a clear reduction in the telomere length was observed in PB cells 218 from the negative control group, a stabilization or even elongation was observed in GT treated 219 patients 2-5 years after infusion of corrected cells. Also of interest is the comparison of the 220 telomere length of PB cells from HDs of the same age, which indicated that telomeres from GT-221 222 treated patients were still below values corresponding to HDs.

223 Overall, the results obtained in this study demonstrate for the first time that GT - in particular the 224 lentiviral-mediated GT in FA patients - reverts the transcriptional program of diseased HSPCs, 225 which then display gene expression signatures, molecular pathways and cellular phenotypes 226 which then resemble the physiological status of healthy HSPCs.

227 DISCUSSION

Gene therapy has emerged as a safe and efficient therapeutic option for diverse monogenic disorders affecting the hematopoietic system (See review in (Ferrari et al., 2021)). In a previous study we showed for the first time preliminary clinical evidence of safety and efficacy of GT in a more complex genetic disease, such as FA (Rio et al., 2019). In that clinical study we demonstrated that the ectopic expression of FANCA reproducibly conferred engraftment and proliferative advantage of corrected HSCs in non-conditioned FA-A patients. Nonetheless, the question of whether corrected FA HSPCs acquire the transcriptional profile characteristic of

It is made available under a CC-BY-NC-ND 4.0 International license .

healthy HSPCs was not addressed in our previous study, nor in any other GT trial of a
 monogenic disease.

By leveraging scRNAseq profiling we have extended the conclusions from our previous study towards the evaluation of changes in the transcriptional program of corrected versus uncorrected HSPCs that coexist in the BM of the same patient. These analyses and also gene expression comparisons performed with respect to HD HSPCs allowed us to demonstrate for the first time that GT not only corrects the expression of the mutated gene (*FANCA* in this case), but also reprograms the molecular circuits of diseased FA-A HSPCs, which then acquire a normalized gene expression pattern characteristic of healthy HSPCs.

Importantly, the restored expression of FANCA decreased the expression of two genes with 244 particular implications in FA, TGF- β and p21. Increased mRNA levels of these two genes have 245 been observed in HSPCs from FA patients and murine FA models and are believed to contribute 246 to the BMF characteristic of the disease (Ceccaldi, Parmar et al., 2012, Zhang, Kozono et al., 247 2016). Notably, previous studies have shown that p21 downregulates USP1 upon exposure to 248 249 DNA damage, disrupting FANCD2/L mono-ubiquitination and nuclear foci formation (Rego et al., 2012). Additional studies have also shown that several genes involved in the telomere 250 251 biology and in the FA/BRCA pathway are downregulated via the p21/E2F4 pathway (Jaber et al., 2016). Although it might be expected that p53 and Myc – which have been shown to be 252 253 upregulated in FA patients (Ceccaldi et al., 2012, Rodríguez, Zhang et al., 2021) – should be also downregulated in corrected FA HSPCs, our data do not support this hypothesis. Reasons 254 255 accounting for these apparent unexpected observations could be related either with the enhanced expression of cell cycle genes in corrected FA HSPCs, with post-transcriptional regulatory 256 257 mechanisms involved in p53 expression (Ceccaldi et al., 2012), or also with the moderate BMF 258 status of the FA patients enrolled in the FANCOLEN I trial (Rio et al., 2019).

Our study also shows that several defective pathways implicated in the FA cellular phenotype were significantly upregulated as a result of the ectopic expression of *FANCA* in FA-A HSPCs. Among all, the restoration of DNA repair related pathways has enormous implications in FA GT since this accounts for the correction of the hypersensitivity of BM progenitors and PB T cells to genotoxic drugs, such as MMC and DEB.

9

It is made available under a CC-BY-NC-ND 4.0 International license .

Also of note was the observation of the increased expression of mini-chromosome maintenance 264 (MCM) helicase genes in corrected FA-A HSPCs. Previous studies have shown that decreased 265 levels of MCM proteins are associated with the HSC hypersensitivity to replication stressors 266 (Flach, Bakker et al., 2014), and have shown a relationship between FA and accelerated ageing 267 (Brosh, Bellani et al., 2017). Strikingly, our study shows for the first time that corrected FA-A 268 HSPCs upregulates the expression of MCM, emulating the MCM expression observed in HD 269 HSPCs, and suggesting that genetic correction should reduce the replication stress and contribute 270 to the rejuvenation of the HSCs from FA patients. Importantly, our study has also shown that GT 271 272 upregulates several genes associated with the telomere biology, and revealed for the first time the maintenance or even elongation of the telomere length in PB cells from FA patients after 2-5 273 years post-GT. This observation contrasts with the progressive telomere attrition previously 274 characterized in FA patients (Savage & Alter, 2008), and also with the negative FA control 275 group included in our study. It is currently unknown whether GT will prevent the progressive 276 telomere attrition characteristic of the disease, or even extend the telomere length of corrected 277 278 hematopoietic cells to levels observed in HD cells.

Taken together, our study demonstrates for the first time that GT reverts the transcriptional program and defective molecular pathways in corrected FA HSPCs. This observation has a particular impact in FA and possibly in other HSC diseases characterized by DNA repair defects, since here we demonstrate that GT restores the molecular pathways of FA HSPCs towards a signature characteristic of healthy HSPCs.

284 MATERIAL AND METHODS

285 **Patients and Healthy donors**

FA patients included in this study, FA-02002, FA-02004, FA-02006 and FA-02008, were FA-A
patients enrolled in the FANCOLEN-1 gene therapy trial (FANCOLEN-1; ClinicalTrials.gov,
NCT03157804; European Clinical Trials Database, 2011-006100-12) and complied with all
relevant ethical regulations approved by the ethics committees at Hospital Vall d'Hebron in
Barcelona and Hospital del Niño Jesús in Madrid.

Patients were infused with autologous CD34⁺ cells after transduction with the therapeutic PGK *FANCA*.Wpre* LV (Gonzalez-Murillo, Lozano et al., 2010). Recent clinical data has shown that

It is made available under a CC-BY-NC-ND 4.0 International license .

although no conditioning was given to these patients prior to cell infusion, a progressive engraftment of corrected cells took place over time, implying the presence of a chimeric population of corrected and uncorrected cells in their hematopoietic tissues (Rio et al., 2019). For the participation of healthy donors (HDs) in this study (median age = 20 y/o), BM aspiration was performed after provision of informed consent, which was approved by the clinical research ethics committee of Clínica Universidad de Navarra.

Bone marrow cells

Bone marrow cells from GT treated patients were obtained in the course of routine follow-up studies of the GT trial and as part of additional exploratory studies. Samples used in these studies were obtained 5 years (FA-02002), 4 years (FA-02004), 3 years (FA-02006) and 2 years (FA-02008) after infusion of transduced CD34⁺ cells, respectively. Patients FA-02004 and FA-02008 had been treated with eltrombopag to stimulate hematopoiesis 12 and 6 months prior to the evaluation of BM cells, respectively. In all instances samples were processed immediately after BM aspiration.

For the purification of CD34⁺ cells, erythrocytes were lysed with ammonium chloride lysis 307 solution (0.155 mmol/L NH₄Cl + 0.01 mmol/L KHCO₃ + 10^{-4} mmol/L EDTA), washed using 308 PBS (Gibco) + 0.2%BSA (10%) + 2% PenStrep (Gibco) and stained using CD45 APC (clone 309 2D1; Biolegend) and CD34 PECY7 (clone 4H11; eBiosciences) for 30 min at 4°C. DAPI was 310 used at a concentration of 1 µg/mL as a viability marker. CD34⁺ cells were then sorted in a BD 311 INFLUXTM (BD Biosciences) or BD FACSAria II (BD Biosciencs) as previously shown (Rio et 312 al., 2019). Purified CD34⁺ cells were directly used for scRNA seq analysis and small aliquots 313 stored at -80°C for vector copy number analysis. 314

315 Analysis of lentiviral vector copy numbers in total BM and purified CD34⁺ cells

The number of proviral copies per cell (VCN/cell) was analyzed after genomic extraction of the 316 DNA using the DNA easy blood and tissue kit (Qiagen) or by proteinase K lysis as previously 317 described(Rio et al., 2019). Duplex qPCR was conducted to detect the Psi sequence of the 318 provirus and the Albumin, as a control gene. To amplify Psi sequence: Psi forward (Psi.F): 5' 319 CAGGACTCGGCTTGCTGAAG 3' 5' 320 and Psi reverse (Psi.R): TCCCCCGCTTAATACTGACG 3' primers were used and detected with the Tagman probe 321 Psi.P FAM: 5'CGCACGGCAAGAGGCGAGG3'. To normalize to endogenous Albumin, 322

It is made available under a CC-BY-NC-ND 4.0 International license .

specific primers for Albumin used: Alb forward (*Alb*.F): 5′ 323 were 3′ Alb 324 GCTGTCATCTCTTGTGGGCTG and reverse (*Alb*.R.): 5′ ACTCATGGGAGCTGCTGGTTC 3' together with a Taqman probe Alb.P VIC: 5' 325 CCTGTCATGCCCACACAAATCTCTCC 3'. qPCR was conducted in an Applied 7500 Fast 326 Real Time PCR system (Thermo Fisher Scientific), as previously described (Rio et al., 2019). 327

328 Single-cell RNA-sequencing (scRNA-seq)

The transcriptome of BM CD34⁺ cells was investigated using NEXTGEM Single Cell 3' Reagent 329 330 Kits v3.1 (10X Genomics) according to the manufacturer's instructions. Between 2.000 and 6.000 CD34⁺ cells were loaded at a concentration of 700-1,000 cells/µL on a Chromium 331 332 Controller instrument (10X Genomics) to generate single-cell gel bead-in-emulsions (GEMs). In this step, each cell was encapsulated with primers containing a fixed Illumina Read 1 used to 333 sequence a cell-identifying 16 bp 10X barcode for each cell and a 12 bp Unique Molecular 334 Identifier (UMI) for each transcript. Upon cell lysis, reverse transcription yielded full-length, 335 336 barcoded cDNA. This cDNA was then released from the GEMs, PCR-amplified and purified with magnetic beads (SPRIselect, Beckman Coulter). Enzymatic Fragmentation and Size 337 Selection was used to optimize cDNA size prior to library construction. Fragmented cDNA was 338 then end-repaired, A-tailed and ligated to Illumina adaptors. A final PCR-amplification with 339 barcoded primers allowed sample indexing. Library quality control and quantification was 340 performed using Qubit 3.0 Fluorometer (Life Technologies) and Agilent's 4200 TapeStation 341 System (Agilent), respectively. Sequencing was performed in a NextSeq500 (Illumina) (Read1: 342 28 cycles; Read 55 cycles; i7 index: 8 cycles) at an average depth of 20,000 reads/cell. 343 According to these analyses CD34⁺ cell populations were classified as *corrected* (FANCA⁺) and 344 uncorrected (FANCA⁻) cells, considering that FANCA⁻ is enriched with cells that only express 345 the endogenous mutated FANCA mRNA, while FANCA⁺, that includes cells with higher 346 FANCA expression, is enriched with cells that express both the endogenous mutated FANCA 347 plus the ectopic functional FANCA mRNA. 348

349 scRNA-seq: bioinformatics

<u>Data filtering and normalization</u>: Sequenced libraries were demultiplexed, aligned to human transcriptome (hg38) and quantified using Cell Ranger (v_3.0.1). Ongoing analysis was conducted using Seurat (V_3.2.0)(Stuart, Butler et al., 2019) in R (V_3.5.2) (Team, 2019).

It is made available under a CC-BY-NC-ND 4.0 International license .

Quality control filters based on the number of detected genes, number of UMIs and percentage of mitochondrial UMIs were performed to each one of the samples. The thresholds were defined based on the distribution of the previously mentioned parameters and visual inspection of quality control scatter plots. After filtering of low quality cells, a total number of 14,208 (FA-02002), 720 (FA-02004), 1,438 (FA-02006), 1,995 (FA-02008), and 12,549 (HD) cells were retained.

Each single cell dataset was individually normalized, using the Normalize Seurat function. Feature counts for each cell were divided by the total counts for that cell and multiplied by the scale factor. This was then natural-log transformed. The data was regressed out by cell cycle stadium, number of features and number of counts. Non-linear dimensional reduction was performed (UMAP) to plot the data of each sample. PCA was defined as dimensional reduction to use in the UMAP graph. Each of the FA samples was integrated with the healthy donor sample.

Cell annotation: For cell annotation, we use the annotation conducted in three additional human 365 samples of healthy young individuals (3YI). The isolation protocol of 3YI includes the cell types 366 in the 4 FA patients and the HD: Ficoll-Paque Plus (GE healthcare) density gradient 367 centrifugation and stained using CD34 (clone 8G12; BD bioscience) CD64 (clone 10.1; 368 Biolegend) CD19 (clone SJ25C1: Biolegend) CD10 (clone HI10A: Biolegend) CD3 (clone 369 OKT3; Biolegend) CD36 (clone CLB-IVC7; Sanquin Plesmanlaan) CD61 (clone RUU-PL7F12; 370 BD bioscience) for 15 min at RT. And finally, CD34+ CD64- CD19- CD10- CD3-CD36+CD61+ 371 cells were then sorted in a BD FACSAria II (BD Biosciences) as previously shown. The data-372 analysis processing of those samples was conducted as the protocol described for FA samples. 373 Next, we performed unsupervised clustering with the Louvain algorithm as implemented in 374 375 Seurat (Blondel, Guillaume et al., 2008). We tested several resolution values and assessed the results by calculating the average silhouette for each cluster. We determined the cluster markers 376 using the Seurat function FindAllMarkers, with the MAST method. Finally, we annotated the 377 clusters in 3YI by manually inspecting the most specific markers and looking for curated 378 379 markers in the literature. Using the robust annotation conducted in 3YI, the "label transfer function" from Seurat was used to annotate the four FA and the HD samples (Stuart et al., 2019). 380 It is important to note that while the annotation of the 3YI is valid for the annotation of FA and 381 HD samples, we decided not to include the 3YI samples in the analysis as the cell proportions 382 383 may be different based on the isolation protocol.

It is made available under a CC-BY-NC-ND 4.0 International license .

Differential expression analysis: The differential expression analysis was conducted using
 FindMarkers function in the Seurat package. Genes were considered differentially expressed if
 |logFC|>0.25 and adjusted p-value<0.05.

<u>GSEA analysis</u>: Gene set enrichment analyses were conducted using ClusterProfiller (version
 3.10.1)(Blondel et al., 2008) in R(Team, 2019). The normalized data of each sample and cell
 type was ranked by the logFC value and the analysis was run comparing our data with GO
 biological processes. A gene set was considered significantly enriched if GO adjusted p value<0.05.

392 **Pathway visualization**

After GSEA analysis two core pathways were selected (Cell cycle and FA/BRCA) for visualization purpose using Cytoscape (version 3.8.2.) (Shannon, Markiel et al., 2003). The values of logFC were for each one of the samples and different contrast using omic visualizer package. The pathways are shown as imported in the Cytoscape package; for two genes an alternative gene symbol is shown (MHF, RPA).

Analysis of the sensitivity of hematopoietic colony forming cells to the genotoxic agent mitomycin C

To assess the influence that gene therapy had in the response of FA hematopoietic progenitors to mitomycin C (MMC), the number of colonies generated in the absence and the presence of this agent was assessed. In these experiments a total number of 2.5×10^5 BM cells were plated in plates containing 1 mL methylcellulose medium (MethocultTM #H4434) supplemented with 10 μ g/mL anti-TNF α and 1 mM N-acetylcysteine, in the absence and the presence of 10 nM MMC (Sigma-Aldrich). Cells were then cultured for 14 days at 37°C, 5% CO₂ and 5% O₂, and colonies were then scored under an inverted microscope.

407 Chromosomal instability test in peripheral blood T cells

The diepoxybutane (DEB)-induced chromosomal instability test was carried out in peripheral blood (PB) T cells from the FA patients prior to and in the long-term after infusion of corrected cells. After 24h of culture, PB cells were incubated in the absence or the presence of DEB $(0.1\mu g/mL;$ Sigma-Aldrich), and forty-six hours later colcemid was added (Gibco; $0.1 \mu g/mL$). Two hours later, metaphase spreads were obtained and stained with Giemsa. Fifty metaphases

It is made available under a CC-BY-NC-ND 4.0 International license .

413 were analyzed from DEB-treated and 25 metaphases from unexposed cultures in a Zeiss Imager

- 414 M1 microscope coupled to a computer assisted metaphase finder (Metasystems). Criteria for the
- determination and quantification of chromosome breakage were previously described (Castella,
- 416 Pujol et al., 2011).

417 **Telomere length studies**

418 DNA was extracted from patient's blood samples and the telomere length was determined by quantitative PCR as previously described (Cawthon, 2002). In this method the amount of 419 telomere DNA (T) and of the single copy 36B4 reference gene (S) were determined by 420 quantitative PCR for each blood sample. The ratio between these two parameters (T/S) was a 421 422 measure of the relative telomere length. A control DNA isolated from the cultured cell line MCF-7 was used as an internal control in each experiment to normalize the T/S ratio obtained for 423 the experimental samples. The telomere length of each sample was calculated from the 424 normalized T/S ratios using the formula: telomere length in Kbp = T/S x 3.86 + 1.89. Three 425 independent experiments with triplicates were conducted for each sample. 426

427 **Basic statistical tests**

- *Proportion test:* In each FA sample and cell type, a two-proportion statistical test was conducted
 to investigate significant differences in cell type proportion between FANCA⁺ and FANCA⁻ cells
 in each CD34⁺ subpopulation.
- Annova test: We conducted a two-tail ANOVA test to investigate the differences of FANCA
 expression between therapy treated patients among the FANCA⁺ set for each CD34⁺ cell
 subpopulation.
- Wilcoxon test: The comparison of the expression of the FANCA gene between FANCA⁺ cells in
 FA integrated samples and HDs was performed using a two-sided Wilcoxon test for each CD34⁺
 cell subpopulation. In HD, only cells with >0 FANCA gene expression value were considered.
- *Binomial Test:* We conducted a binomial test to investigate if the shared directionality of changes for two contrasts, "FANCA⁺ vs FANCA⁻" and "HD vs FANCA⁺", was significantly overrepresented. To this end, the genes sharing the same directionality for both contrasts were classified as 1, and 0 otherwise; the binomial was conducted considering a probability of 0.5,

It is made available under a CC-BY-NC-ND 4.0 International license .

number of experiments of 382 and a one-tail p-value associated to values larger than the
 observed. The analysis was conducted separately for each cell type and sample.

Binary Correlation: We conducted a binary correlation analysis between the directionality of the same genes in the two contrasts, "FANCA⁺ vs FANCA⁻" and "HD vs FANCA⁺". All the upregulated genes were classified as 1 and the downregulated as 0. A binary correlation test was conducted using R.

- General considerations: To perform all the statistical tests R (Team, 2019) was used. In all the
 cases the multiple testing was addressed using Bonferroni; and for any analysis the null
 hypothesis was rejected if adjusted p-value <0.05.
- 450

452

451 ACKNOWLEDGMENTS

453 The authors thank Ramón García-Escudero for careful reading of the manuscript and helpful discussions. The authors also thank A. de la Cal for coordinating the delivery of BM samples 454 455 from patients with FA. The authors are also indebted to the patients with FA, their families and clinicians from the Fundación Anemia de Fanconi. This work was supported by grants from the 456 457 European Commission's Seventh Framework Program (HEALTH-F5-2012-305421) to the EUROFANCOLEN Consortium J.B. and J.Se; from Ministerio de Ciencia, Innovación y 458 Universidades and Fondo Europeo de Desarrollo Regional (RTI2018-097125-B-I00 to P.R. and 459 S.N.); from Gobierno de Navarra, Departamento de Desarrollo Económico y Empresarial 460 (AGATA 0011-1411-2020-000010); from Instituto de Salud Carlos III (ISCIII) and co-financed 461 by FEDER CIBERONC (CB16/12/00489 and CB16/12/00225); Redes de Investigación 462 Cooperativa (TERCEL RD16/0011/0005) and from Consejería de Educación, Juventud y 463 Deporte de la Comunidad de Madrid (AvanCell Project; B2017/BMD3692); from Fondo de 464 Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain, grant number PI20/0335 and co-465 funded by European Regional Development (FEDER) funds. M.A. was supported by a PhD 466 Fellowship from Ministerio de Ciencia, Innovación y Universidades (FPU18/05488). CIBERER 467 and CIBERONC are initiatives of the Instituto de Salud Carlos III and Fondo Europeo de 468 Desarrollo Regional. 469

470 AUTHORSHIP CONTRIBUTIONS

It is made available under a CC-BY-NC-ND 4.0 International license .

M.L., P.R., A.V-Z., N.P., S.N., D.A, B.F-V, R.M.J, M.A, A.U-A., R.P, L.S and D-G.C
performed the experimental studies and analyzed the data. J.Se. and J.Z. provided critical
materials. M.L., P.R., D-G.C, F.P. J.A.B wrote the manuscript. E.N. and J.D.S. reviewed the
manuscript. P.R., S.N., D-G.C, F.P. J.A.B designed the study. All authors discussed the results
and contributed to the preparation of the manuscript.

476 **CONFLICT OF INTEREST**

The Hematopoietic Innovative Therapies Division at CIEMAT receives funding and has licensed the PGK-FANCA-WPRE* lentiviral vector to Rocket Pharmaceuticals. J.A.B. and J.Se. are consultants for Rocket Pharmaceuticals. E.N. and J.D.S. are employees of Rocket Pharmaceuticals. P.R., S.N., J.S and J.A.B. are inventors on patents filed by CIEMAT, CIBERER and Fundación Jiménez Díaz, and may be entitled to receive financial benefits from the licensing of such patents. The rest of the authors declare that they have no competing interests.

484 THE PAPER EXPLAINED

PROBLEM: HSC gene therapy of monogenic diseases has already demonstrated clinical
 efficacy in a variety of monogenic disorders, including HSC diseases such as Fanconi anemia
 (FA). Nevertheless, the question of whether or not these therapies can correct the transcriptional
 program of target cells, in particular of diseased HSCs, has never been addressed.

RESULTS: In this study we demonstrate that gene therapy reverts the transcriptional signature of HSPCs from patients with FA. Remarkably, these HSCs changed their transcriptional program, to resemble the one corresponding to healthy donor HSPCs, and this is associated with the phenotypic correction of FA HSPCs.

IMPACT: Our results show for the first time the potential of gene therapy to rescue defects in
 the HSPC transcriptional program from patients with inherited diseases, in this particular case in
 a disease characterized by profound defects in the HSCs.

496 FOR MORE INFORMATION

497 <u>https://anemiadefanconi.org/</u>

It is made available under a CC-BY-NC-ND 4.0 International license .

- 498 <u>http://www.fanconi.org/</u>
- 499

500 DATA SHARING STATEMENT

- 501 Data supporting the findings of this study are available at:
- 502 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE180536

It is made available under a CC-BY-NC-ND 4.0 International license .

503 **REFERENCES**

504

- Blondel VD, Guillaume J-L, Lambiotte R, Lefebvre E (2008) Fast unfolding of communities in
 large networks. Journal of Statistical Mechanics: Theory and Experiment P10008
- 507 Brosh RM, Jr., Bellani M, Liu Y, Seidman MM (2017) Fanconi Anemia: A DNA repair disorder 508 characterized by accelerated decline of the hematopoietic stem cell compartment and other 509 features of aging. Ageing Res Rev 33: 67-75
- 510 Castella M, Pujol R, Callen E, Ramirez MJ, Casado JA, Talavera M, Ferro T, Munoz A, Sevilla
- J, Madero L, Cela E, Belendez C, de Heredia CD, Olive T, de Toledo JS, Badell I, Estella J, Dasi
- 512 A, Rodriguez-Villa A, Gomez P et al. (2011) Chromosome fragility in patients with Fanconi
- anaemia: diagnostic implications and clinical impact. J Med Genet 48: 242-50
- 514 Cawthon RM (2002) Telomere measurement by quantitative PCR. Nucleic Acids Res 30: e47
- 515 Ceccaldi R, Parmar K, Mouly E, Delord M, Kim JM, Regairaz M, Pla M, Vasquez N, Zhang QS,
- 516 Pondarre C, Peffault de Latour R, Gluckman E, Cavazzana-Calvo M, Leblanc T, Larghero J,
- 517 Grompe M, Socie G, D'Andrea AD, Soulier J (2012) Bone marrow failure in Fanconi anemia is 518 triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and 519 progenitor cells. Cell stem cell 11: 36-49
- Ferrari G, Thrasher AJ, Aiuti A (2021) Gene therapy using haematopoietic stem and progenitor
 cells. Nat Rev Genet 22: 216-234
- Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, Alvarez S, Diolaiti ME,
 Ugarte F, Forsberg EC, Le Beau MM, Stohr BA, Mendez J, Morrison CG, Passegue E (2014)
 Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells.
 Nature 512: 198-202
- Gonzalez-Murillo A, Lozano ML, Alvarez L, Jacome A, Almarza E, Navarro S, Segovia JC,
 Hanenberg H, Guenechea G, Bueren JA, Rio P (2010) Development of lentiviral vectors with
 optimized transcriptional activity for the gene therapy of patients with Fanconi anemia. Hum
 Gene Ther 21: 623-30
- Jaber S, Toufektchan E, Lejour V, Bardot B, Toledo F (2016) p53 downregulates the Fanconi
 anaemia DNA repair pathway. Nature communications 7: 11091

It is made available under a CC-BY-NC-ND 4.0 International license .

- Rego MA, Harney JA, Mauro M, Shen M, Howlett NG (2012) Regulation of the activation of the
 Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. Oncogene 31: 366-75
- Rio P, Navarro S, Wang W, Sanchez-Dominguez R, Pujol RM, Segovia JC, Bogliolo M, Merino
- 535 E, Wu N, Salgado R, Lamana ML, Yanez RM, Casado JA, Gimenez Y, Roman-Rodriguez FJ,
- 536 Alvarez L, Alberquilla O, Raimbault A, Guenechea G, Lozano ML et al. (2019) Successful
- 537 engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi
- anemia. Nat Med 25: 1396-1401
- 539 Rodríguez A, Zhang K, Färkkilä A, Filiatrault J, Yang C, Velázquez M, Furutani E, Goldman
- 540 DC, García de Teresa B, Garza-Mayén G, McQueen K, Sambel LA, Molina B, Torres L,
- 541 González M, Vadillo E, Pelavo R, Fleming WH, Grompe M, Shimamura A et al. (2021) MYC
- 542 Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia. Cell stem cell 28: 33-47.e8

It is made available under a CC-BY-NC-ND 4.0 International license .

- 543 Savage SA, Alter BP (2008) The role of telomere biology in bone marrow failure and other 544 disorders. Mech Ageing Dev 129: 35-47
- 545 Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B,
- Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular
 interaction networks. Genome Res 13: 2498-504
- 548 Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, Hao Y, Stoeckius
- 549 M, Smibert P, Satija R (2019) Comprehensive Integration of Single-Cell Data. Cell 177: 1888550 1902.e21
- Team RC (2019) A language and environment for statistical computing. R Foundation for
 Statistical Computing, Vienna, Austria.
- 553 Velten L, Haas SF, Raffel S, Blaszkiewicz S, Islam S, Hennig BP, Hirche C, Lutz C, Buss EC,
- Nowak D, Boch T, Hofmann WK, Ho AD, Huber W, Trumpp A, Essers MA, Steinmetz LM
 (2017) Human haematopoietic stem cell lineage commitment is a continuous process. Nat Cell
- 556 Biol 19: 271-281
- Zhang H, Kozono DE, O'Connor KW, Vidal-Cardenas S, Rousseau A, Hamilton A, Moreau L,
 Gaudiano EF, Greenberger J, Bagby G, Soulier J, Grompe M, Parmar K, D'Andrea AD (2016)
 TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in
 Fanconi Anemia. Cell stem cell 18: 668-81
- Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, Ziraldo SB, Wheeler TD,
 McDermott GP, Zhu J, Gregory MT, Shuga J, Montesclaros L, Underwood JG, Masquelier DA,
 Nishimura SY, Schnall-Levin M, Wyatt PW, Hindson CM, Bharadwaj R et al. (2017) Massively
 parallel digital transcriptional profiling of single cells. Nature communications 8: 14049
- 565
- 566

It is made available under a CC-BY-NC-ND 4.0 International license .

567 **FIGURE LEGENDS**

568

Figure 1. Experimental design of scRNAseq analyses performed in FA-A patients 2-5 years 569 570 after lentiviral-mediated gene therapy. Four FA-A patients who had been treated by ex vivo lentiviral-mediated gene therapy in the absence of conditioning were included in this study. At 2-571 572 5 years post-gene therapy, these patients harbored a chimeric population of corrected and uncorrected hematopoietic stem and progenitor cells (HSPCs) in their bone marrow (BM). 573 574 Aliquots of BM CD34⁺ cells from these patients were sorted and processed for single-cell RNAseq. Bioinformatic analyses were then conducted to comparatively investigate changes in the 575 transcriptional program of corrected versus uncorrected HSPCs, coexisting in each of the gene 576 therapy treated patients. 577

578 Figure 2. scRNAseq analysis of corrected and uncorrected hematopoietic stem and 579 progenitor cells from FA-A patients 2-5 years after lentiviral-mediated gene therapy.

(A) UMAP plot showing the clustering analysis for BM CD34⁺ cells from a FA-A patient 580 previously treated by gene therapy (FA-02006 patient as an example; see Fig. S1 for patients 581 FA-02002, FA-02004 and FA-02008). A total of 12 clusters were identified, spanning the 582 different HSPC subpopulations. Identified clusters include an HSC cluster (hematopoietic stem 583 cell; brown). Clusters with megakaryocytic-erythroid identity include MEP (erythroid-584 megakaryocyte progenitor; purple), Erythroid (erythroid progenitor; pink), and Basophils 585 (basophil progenitor; light pink). Clusters with lympho-myeloid identity include LMPP 586 (lymphoid-primed multipotent progenitor; light blue), Cycling-LMPP (blue), CLP (common 587 lymphoid progenitor; orange), GMP1 and GMP2 (granulocyte-monocyte progenitor; light green 588 and green), Monocytes (monocyte progenitor; red), DC (dendritic cell progenitor; nude), and 589 PreB (B cells progenitor; light purple). (B) The same UMAP as shown in panel A, highlighting 590 the distribution of FANCA⁺ cells (FANCA mRNA detectable; red) versus FANCA⁻ cells 591 (FANCA mRNA levels are below detection limit; blue). (C) Barplot showing the total number 592 of cells in the different HSPC populations corresponding to the four gene therapy treated 593 patients. In each case, the number of FANCA⁺ (red) and FANCA⁻ (blue) cells is shown and the 594 percentage represented by $FANCA^+$ is written in the top of the bar. (D) Boxplot of integrated 595 and normalized FANCA gene expression in FANCA⁺, depicted by cell type and FA individual 596 (n=3). (E) Barplot representation of the differential expression analysis between FANCA⁺ and 597

It is made available under a CC-BY-NC-ND 4.0 International license .

FANCA⁻ for each FA patient (n=4) and for each of the HSPC populations. In each case, the number of upregulated and downregulated genes is shown. Upregulated genes were defined as logFC>0.25 (orange), upregulated and significant genes were defined as a logFC>0.25 and adjusted p-value<0.05 (red), downregulated genes were defined as a logFC<-0.25 (light blue) and downregulated and significant genes were define as logFC<-0.25 and adjusted p-value<0.05 (dark blue). The number of genes with the same behavior (upregulated or downregulated) in the four individuals is shown below each HSPCs (labeled as "*shared*").

Figure 3. Comparisons of the gene expression signature between corrected and uncorrected HSPCs coexisting in gene therapy treated FA patients.

(A) Left larger panel: UMAP plot showing the clustering analysis of CD34⁺ BM cells after 607 integration of data from a gene therapy treated FA-A patient and a healthy donor (FA-02006 is 608 included as a representative example; see Fig. S2 for the rest of individuals). Right smaller 609 **panel**: the same UMAP as shown in left panel but highlighting the distribution of HD HSPCs 610 (yellow), FANCA⁺ HSPCs (red) and FANCA⁻ HSPCs (blue). Clusters identification as in Figure 611 1. (B) Boxplot representation of normalized single-cell FANCA expression of FANCA⁺ cells 612 (red) and HD cells (yellow) by HSPC cluster. For each cell type, differences in the expression 613 levels between the ectopic expression of FANCA from corrected FA CD34⁺ cells and expression 614 levels corresponding to HD CD34⁺ cells are shown (*adjusted p-value <0.05; **adjusted p-value 615 < 0.01; ***adjusted p-value < 0.001) (C) The figure shows the results associated to three 616 differential expression contrasts: FANCA⁺ vs FANCA⁻ HSPCs from GT-treated FA patients; HD 617 HSPCs vs FANCA⁻ HSPCs from GT-treated patients; and HD HSPCs vs FANCA⁺ HSPCs from 618 GT-treated patients. The second row shows the twelve different CD34⁺ cell types, and the third 619 620 one the sample identification from each of the four GT-treated patients. Up-regulated genes (logFC>0) are shown in orange and those with significant upregulation in red (logFC>0.25 and 621 adjusted p-value<0.05). Down-regulated genes (logFC<0) are shown in light blue and those with 622 significant downregulation in dark blue (logFC<-0.25 and adjusted p-value<0.05). Unsupervised 623 hierarchical clustering using Pearson distance and average linkage method was applied for gene 624 625 classification. The genes included in the heatmap are those that for at least one cell type are identified as differentially expressed (abs(logFC)>0.25 and adjusted p-value<0.05) in "at least 626 three patients", and "showing the same direction of the change for the three patients", when 627

It is made available under a CC-BY-NC-ND 4.0 International license .

628 considering the contrast FANCA⁺ vs FANCA⁻ (n=152; see the entire list in Table S2). FANCA 629 was excluded from the list.

Figure 4. Restored gene expression pathways associated to the ectopic expression of FANCA in HSPCs from gene therapy treated FA patients.

- Comparative density plots showing the distribution of differential expression derived logFC for a 632 selected set of pathways. For each patient, paired comparisons between FANCA⁺ vs FANCA⁻ 633 HSPCs from GT-treated FA patients and HD HSPCs vs FANCA⁻ HSPCs are shown. The 634 complete name of the pathways with numbers are: (1) DNA damage response, detection of DNA 635 damage, (2) telomere maintenance via semi-conservative replication, (3) double-strand break 636 repair via homologous recombination, (4) double-strand break repair via nonhomologous end 637 joining, (5) positive regulation of G2/M transition of mitotic cell cycle, and (6) negative 638 regulation of G2/M transition of mitotic cell cycle. 639
- Figure 5. Restored gene expression of key pathways in corrected HSPCs from gene therapy
 treated FA patients.

(A) Upregulated and downregulated genes implicated in cell cycle control. The figure represents
the logFC associated to two contrasts: FANCA⁺ vs FANCA⁻ HSPCs from GT-treated FA
patients (internal crowns), and HD HSPCs vs FANCA⁻ HSPCs from GT-treated patients
(external crowns). Each external and internal crown is divided in four parts, each of them
representing one FA patient. Upregulated genes are shown in red and downregulated genes in
blue. (B) Same representation as in A showing changes in the expression of genes participating
in the FA/BRCA pathway.

649

Figure 6: Functional implications associated to the restoration of DNA repair and telomere biology pathways

(A) Survival to mitomycin C (MMC; 10 nM) of BM colony forming cells (CFCs) from FA-A patients shown in Figures 1-5 prior and after infusion of gene corrected cells. (B) Percentage of PB T cells with chromosomal aberrations induced by diepoxibutane (DEB), prior to and after gene therapy. (C) Analysis of the telomere length of PB cells from FA-A patients shown in Figures 1-5 at 15th day post-infusion, when corrected cells were still undetectable, to the 2nd -5th year post-infusion of gene corrected cells. As a negative control, three FA patients with no

It is made available under a CC-BY-NC-ND 4.0 International license .

significant engraftment of gene corrected cells are included. Dashed lines correspond to telomere
 lengths corresponding to HD age matched PB cells. Time-points of the MMC, DEB and telomere
 analyses are the same or the closest ones corresponding to the scRNAseq analyses shown in
 Figures 1-5.

662 663

664 **EXPANDED VIEW FIGURES LEGENDS**

665 Expanded view Figure S1: (A) Left panel: UMAP plot showing the clustering analysis for CD34⁺ BM cells from the FA-02002 patient undergoing FANCA gene therapy. A total of 12 666 clusters were identified, spanning the different HSPC subpopulations. Identified clusters include 667 an HSC cluster (hematopoietic stem cell; brown). Clusters with megakaryocytic-erythroid 668 669 identity include MEP (erythroid-megakaryocyte progenitor; purple), Erythroid (erythroid progenitor; pink), and Basophils (basophil progenitor; light pink). Clusters with lympho-myeloid 670 identity include LMPP (lymphoid-primed multipotent progenitor; light blue), Cycling-LMPP 671 (blue), CLP (common lymphoid progenitor; orange), GMP1 and GMP2 (granulocyte-monocyte 672 progenitor; light green and green), Monocytes (monocyte progenitor; red), DC (dendritic cell 673 progenitor; nude), and PreB (B cells progenitor; light purple). Right panel: Distribution of 674 FANCA positive cells (corrected cells; red) versus FANCA negative cells (uncorrected cells; 675 blue). (**B**, **C**) Same as (A), including the analysis of the FA-02004 and FA-02008 respectively 676 patient. (D) Cell type proportions for each individual separating in each case FANCA⁺ and 677 FANCA⁻ cells. 678

679

Expanded view Figure S2: (A) UMAP plot showing the clustering analysis for CD34⁺ BM cells 680 from the FA-02002 patient undergoing FANCA gene therapy and the healthy donor. A total of 681 12 clusters were identified, spanning the different HSPC subpopulations. Identified clusters 682 include an HSC cluster (hematopoietic stem cell; brown). Clusters with megakaryocytic-683 erythroid identity include MEP (erythroid-megakaryocyte progenitor; purple), Erythroid 684 (erythroid progenitor; pink), and Basophils (basophil progenitor; light pink). Clusters with 685 lympho-myeloid identity include LMPP (lymphoid-primed multipotent progenitor; light blue), 686 Cycling-LMPP (blue), CLP (common lymphoid progenitor; orange), GMP1 and GMP2 687 (granulocyte-monocyte progenitor; light green and green), Monocytes (monocyte progenitor; 688

It is made available under a CC-BY-NC-ND 4.0 International license .

- red), DC (dendritic cell progenitor; nude), and PreB (B cells progenitor; light purple). (**B**, **C**)
- Same as (A), including the analysis of the FA-02004 and FA-02008 respectively patient. (D)
- Distribution of cells classified as cells derived from the healthy donor (yellow), FANCA⁺ cells
- (red) and FANCA⁻ cells (blue) for FA-02002 patient. (**E**, **F**) Same as (D) including the analysis
- 693 of the FA-02004 and FA-02008 respectively patient.







10x Genomics Chromium Single Cell Gene Expression

VS. **Data analysis** Changes derived from

gene therapy. Figure 1

Autologous HSC gene therapy

Chimeric BM

BM CD34+ cell sorting



Figure 2





Figure 3



A Cell cycle - Monocytes

B FA/BRCA - Monocytes

